content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font-size: 10pt">
  
  <P STYLE="margin: 0"></P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in"></P>
  
  <P STYLE="margin: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>
  
  <P STYLE="margin: 0; text-align: center">Washington, D.C. 20549</P>
  
  <P STYLE="margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: center"><B>FORM 8-K</B></P>
  
  <P STYLE="margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: center">CURRENT REPORT</P>
  
  <P STYLE="margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: center">Pursuant to Section 13 or 15(d)</P>
  
  <P STYLE="margin: 0; text-align: center">of the Securities Exchange Act of 1934</P>
  
  <P STYLE="margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: center">Date of Report (date of earliest event
  reported):</P>
  
  <P STYLE="margin: 0; text-align: center">July 8, 2016</P>
  
  <P STYLE="margin: 0; text-align: center">&nbsp;&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="background-color: white">
      <TD COLSPAN="5" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EVENT
      CARDIO GROUP INC.</B></FONT></TD></TR>
  <TR STYLE="background-color: white">
      <TD COLSPAN="5" STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
      name of registrant as specified in its charter)</FONT></TD></TR>
  <TR STYLE="background-color: white">
      <TD COLSPAN="5" STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
      <TD STYLE="width: 5%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>0-52518</B></FONT></TD>
      <TD STYLE="width: 5%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20-8051714</B></FONT></TD></TR>
  <TR>
      <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
      or other jurisdiction of Incorporation)</FONT></TD>
      <TD STYLE="vertical-align: top; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
      File Number)</FONT></TD>
      <TD STYLE="vertical-align: top; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="vertical-align: top; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
      Employer Identification No.)</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 51%; border-bottom: black 1pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>739
                                           Colony Palm Drive</B></FONT></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Boynton
          Beach, Florida </B></FONT></P></TD>
      <TD STYLE="width: 6%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 43%; border-bottom: black 1pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>33436</B></FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;(Address of
  principal executive offices)</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify">Check the appropriate box below if
  the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
  (see General Instruction A.2. below):</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 15pt; text-align: right">[ ]</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD>
  </TR></TABLE>
  
  
  <P STYLE="margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 15pt; text-align: right">[ ]</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17&nbsp;&nbsp;&nbsp;CFR
  240.14a-12)</TD>
  </TR></TABLE>
  
  
  <P STYLE="margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 15pt; text-align: right">[ ]</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
  CFR 240.14d-2(b))</TD>
  </TR></TABLE>
  
  
  <P STYLE="margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 15pt; text-align: right">[ ]</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
  CFR 240.13e-4(c))</TD>
  </TR></TABLE>
  
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0"></P></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify"><B>Item 2.01 Completion of Acquisition
  or Disposition of Assets.</B></P>
  
  <P STYLE="margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify">On July 8, 2016, Event Cardio Group Inc., a Nevada corporation (the
  &ldquo;Company&rdquo;), acquired all of the outstanding shares of Ambumed, Inc., a Maryland corporation
  (&ldquo;Ambumed&rdquo;), pursuant to a Stock Purchase Agreement dated June 30, 2016 with Richard Oswik and Joseph Hashim
  (together, the &ldquo;Shareholders&rdquo;) of Ambumed (the &ldquo;Ambumed Stock Purchase Agreement&rdquo;). The consideration
  for the acquisition consisted of $1,200,000, of which $600,000 was paid at closing and $600,000 is payable on the first
  anniversary of the closing, together with two million (2,000,000) restricted shares of the Company&rsquo;s common stock, of
  which 500,000 shares were deposited in escrow to satisfy the indemnification obligations of the Shareholders. The number of
  shares issued to the Shareholders is subject to adjustment if the market price of the common stock for the ten trading days
  preceding August 1, 2017 is less than $0.25 per share.&nbsp;In connection with the acquisition, as a result of which Ambumed
  has become a wholly-owned subsidiary of the Company, the Company entered into an employment agreement with Joseph Hashim to
  serve as Chief Operating Officer of Ambumed until July 31, 2020. Under the employment agreement Mr. Hashim is entitled to an
  initial salary of $150,000 during the first year ofthe agreement, $200,000 for the second year and $250,000 thereafter, plus
  a bonus of up to $100,000 commencing in the second year if certain specified performance target are achieved.&nbsp;The agreement
  also grants Mr. Hashim 3,000,000 restricted shares of the Company&rsquo;s common stock, subject to specified
  vesting criteria, plus options to purchase on or before July 31, 2020 up to an additional 1,000,000 shares of the
  Company&rsquo;s common stock at an initial exercise price of $0.15 per share, subject to adjustment for certain anti-dilution
  events, such as stock splits and upon the occurrence of fundamental transactions such as mergers and other business
  combinations.</P>
  
  <P STYLE="margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify">Ambumed provides electrocardiography
  support services designed specifically for physicians, hospitals, scanning services and home health care agencies, including a
  24-hour/day ECG monitoring center, under the name National Cardiac Monitoring Center.</P>
  
  <P STYLE="margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify"><B>Item 3.02 Unregistered Sales of
  Equity Securities.</B></P>
  
  <P STYLE="margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="margin: 0; text-align: justify">On July 8, 2016, the Company issued
  1,000,000 shares of the Company&rsquo;s common stock to each of Richard Oswik and Joseph Hashim as part of the consideration for
  the acquisition of all of the outstanding shares of Ambumed. The shares were issued pursuant to the exemption from registration
  provided by Section 4(a)(2) of the Securities Act. The Company did not pay any sales commissions or broker fees in connection
  with the issuance of the shares. The certificates evidencing the shares were endorsed with a legend restricting their sale or
  other disposition without compliance with the registration requirements of the Securities Act or an exemption therefrom.</P>
  
  <P STYLE="margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify"><B>Item 7.01 Regulation FD Disclosure.</B></P>
  
  <P STYLE="margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="margin: 0; text-align: justify">On July 11, 2016, the Company issued a press
  release announcing the acquisition of Ambumed. The press release is attached as Exhibit 99.1 to this report.</P>
  
  <P STYLE="margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify">The information in Exhibit 99.1 shall not
  be deemed as &ldquo;filed&rdquo; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;),
  or otherwise subject to the liability of such Section, nor shall it be deemed incorporated by reference in any filing by us under
  the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing,
  unless expressly incorporated by specific reference in such filing.</P>
  
  <P STYLE="margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify"><B></B></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0"></P></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="margin: 0; text-align: justify"><B>Item 9.01 Financial Statements and
  Exhibits</B>.</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 5.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                           statements. The Company will file an amendment to this report to include the financial
                                           statements of Ambumed within 71 days &nbsp;after the date of this report as permitted
                                           pursuant to paragraph (a)(1) (iv) of this Item 9.01.</FONT></TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 5.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
                                           forma financial information. The Company will file an amendment to this report to include
                                           the pro forma financial information concerning the Company as a result of the acquisition
                                           of Ambumed within 71 days &nbsp;after the date of this report as permitted pursuant to
                                           paragraph (a)(1) (iv) of this Item 9.01.</FONT></TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 5.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
      Number</FONT></TD>
      <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="border-bottom: black 1pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
      <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="vertical-align: top"><P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 102.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
          <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ecgi8k071416ex10_1.htm">Ambumed Stock Purchase Agreement dated June 30, 2016 (incorporated herein by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed on July 7, 2016).&#9;</A></FONT></P></TD></TR>
  <TR>
      <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
      <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ecgi8k071416ex10_2.htm">Promissory Note issued to Richard Oswik.</A></FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
      <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ecgi8k071416ex10_3.htm">Promissory Note issued to Joseph Hashim.</A></FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
      <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ecgi8k071416ex10_4.htm">Employment Agreement dated July 8, 2016 with Joseph Hashim.</A></FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
      <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ecgi8k071416ex10_5.htm">Press release issued by the Company on July 13, 2016.</A></FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 57.75pt"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">SIGNATURES</P>
  
  <P STYLE="margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify">Pursuant to the requirements of the
  Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
  duly authorized.</P>
  
  <P STYLE="margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify">Dated: July 14, 2016</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD COLSPAN="2" STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVENT
      CARDIO GROUP INC.</FONT></TD>
      <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 54%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 35%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 10%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
      <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;John
      Bentivoglio</FONT></TD>
      <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
      Bentivoglio</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
      <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 6pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 3; Options: Last -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0"></P></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0 0 8pt"></P>
  
  <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>
  
  
  
  <P STYLE="margin: 0"></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "ecgi8k071416.htm", "secsgml_size_bytes": 24661}]
metadata_filer: {"company-data": {"conformed-name": "Event Cardio Group Inc.", "cik": "0001394130", "assigned-sic": "1000", "irs-number": "208051714", "state-of-incorporation": "NV", "fiscal-year-end": "0831"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-52518", "film-number": "161769038"}, "business-address": {"street1": "2798 THAMESGATE DR.", "city": "MISSISSAUGA", "state": "A6", "zip": "L4T 4E8", "phone": "289-407-4377"}, "mail-address": {"street1": "2798 THAMESGATE DR.", "city": "MISSISSAUGA", "state": "A6", "zip": "L4T 4E8"}, "former-company": [{"former-conformed-name": "Sunrise Holdings LTD", "date-changed": "20080404"}, {"former-conformed-name": "Sunrise Mining CORP", "date-changed": "20070322"}]}
text: SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM 8-K
  CURRENT REPORT
  Pursuant to Section 13 or 15(d)
  of the Securities Exchange Act of 1934
  Date of Report (date of earliest event
  reported):
  July 8, 2016
  EVENT
      CARDIO GROUP INC.
  (Exact
      name of registrant as specified in its charter)
  Nevada
  0-52518
  20-8051714
  (State
      or other jurisdiction of Incorporation)
  (Commission
      File Number)
  (I.R.S.
      Employer Identification No.)
  739
                                           Colony Palm Drive
  Boynton
          Beach, Florida
  33436
  (Address of
  principal executive offices)
  Check the appropriate box below if
  the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
  (see General Instruction A.2. below):
  [ ]
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  [ ]
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17   CFR
  240.14a-12)
  [ ]
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
  CFR 240.14d-2(b))
  [ ]
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
  CFR 240.13e-4(c))
  Item 2.01 Completion of Acquisition
  or Disposition of Assets.
  On July 8, 2016, Event Cardio Group Inc., a Nevada corporation (the
  "Company"), acquired all of the outstanding shares of Ambumed, Inc., a Maryland corporation
  ("Ambumed"), pursuant to a Stock Purchase Agreement dated June 30, 2016 with Richard Oswik and Joseph Hashim
  (together, the "Shareholders") of Ambumed (the "Ambumed Stock Purchase Agreement"). The consideration
  for the acquisition consisted of $1,200,000, of which $600,000 was paid at closing and $600,000 is payable on the first
  anniversary of the closing, together with two million (2,000,000) restricted shares of the Company's common stock, of
  which 500,000 shares were deposited in escrow to satisfy the indemnification obligations of the Shareholders. The number of
  shares issued to the Shareholders is subject to adjustment if the market price of the common stock for the ten trading days
  preceding August 1, 2017 is less than $0.25 per share. In connection with the acquisition, as a result of which Ambumed
  has become a wholly-owned subsidiary of the Company, the Company entered into an employment agreement with Joseph Hashim to
  serve as Chief Operating Officer of Ambumed until July 31, 2020. Under the employment agreement Mr. Hashim is entitled to an
  initial salary of $150,000 during the first year ofthe agreement, $200,000 for the second year and $250,000 thereafter, plus
  a bonus of up to $100,000 commencing in the second year if certain specified performance target are achieved. The agreement
  also grants Mr. Hashim 3,000,000 restricted shares of the Company's common stock, subject to specified
  vesting criteria, plus options to purchase on or before July 31, 2020 up to an additional 1,000,000 shares of the
  Company's common stock at an initial exercise price of $0.15 per share, subject to adjustment for certain anti-dilution
  events, such as stock splits and upon the occurrence of fundamental transactions such as mergers and other business
  combinations.
  Ambumed provides electrocardiography
  support services designed specifically for physicians, hospitals, scanning services and home health care agencies, including a
  24-hour/day ECG monitoring center, under the name National Cardiac Monitoring Center.
  Item 3.02 Unregistered Sales of
  Equity Securities.
  On July 8, 2016, the Company issued
  1,000,000 shares of the Company's common stock to each of Richard Oswik and Joseph Hashim as part of the consideration for
  the acquisition of all of the outstanding shares of Ambumed. The shares were issued pursuant to the exemption from registration
  provided by Section 4(a)(2) of the Securities Act. The Company did not pay any sales commissions or broker fees in connection
  with the issuance of the shares. The certificates evidencing the shares were endorsed with a legend restricting their sale or
  other disposition without compliance with the registration requirements of the Securities Act or an exemption therefrom.
  Item 7.01 Regulation FD Disclosure.
  On July 11, 2016, the Company issued a press
  release announcing the acquisition of Ambumed. The press release is attached as Exhibit 99.1 to this report.
  The information in Exhibit 99.1 shall not
  be deemed as "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"),
  or otherwise subject to the liability of such Section, nor shall it be deemed incorporated by reference in any filing by us under
  the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing,
  unless expressly incorporated by specific reference in such filing.
  Item 9.01 Financial Statements and
  Exhibits
  .
  (a)
  Financial
                                           statements. The Company will file an amendment to this report to include the financial
                                           statements of Ambumed within 71 days  after the date of this report as permitted
                                           pursuant to paragraph (a)(1) (iv) of this Item 9.01.
  (b)
  Pro
                                           forma financial information. The Company will file an amendment to this report to include
                                           the pro forma financial information concerning the Company as a result of the acquisition
                                           of Ambumed within 71 days  after the date of this report as permitted pursuant to
                                           paragraph (a)(1) (iv) of this Item 9.01.
  (c)
  Exhibit
      Number
  Description
  10.1
  Ambumed Stock Purchase Agreement dated June 30, 2016 (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 7, 2016).
  10.2
  Promissory Note issued to Richard Oswik.
  10.3
  Promissory Note issued to Joseph Hashim.
  10.4
  Employment Agreement dated July 8, 2016 with Joseph Hashim.
  10.5
  Press release issued by the Company on July 13, 2016.
  SIGNATURES
  Pursuant to the requirements of the
  Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
  duly authorized.
  Dated: July 14, 2016
  EVENT
      CARDIO GROUP INC.
  By:
  /s/ John
      Bentivoglio
  John
      Bentivoglio
  Chief Executive Officer